Worth reading
51Recurring
Scored from 5 of 6 sectionsDirection
Deterioration
Direction inferred from the company’s description.Scale
-49.3
Year-on-year revenue growth (%)Wording
Conditional
How definitive the wording is.Results for this period
First quarter2023年7月1日〜2023年9月30日ConsolidatedJapanese GAAPNet Sales1,124,626¥ thousandYear on year -49.3%
Operating profit-501,031¥ thousand
Ordinary income-496,402¥ thousand
Net income attributable to owners of the parent-527,096¥ thousand
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
Financial position at period-end
Total assets7,415,538¥ thousand
of which net assets 6,513,457 ¥ thousand
The shaded area represents net assets as a proportion of total assets. It is calculated from the two amounts reported by the company.
Segment revenueBiological Assessment Systems ¥57,145 thousand (YoY -35.9%), Healthcare Support ¥157,441 thousand (YoY +6.6%), Cosmetics ¥165,871 thousand (YoY -85.1%), Health Supplements ¥676,141 thousand (YoY -7.6%), Functional Materials Development ¥67,426 thousand (YoY -51.0%)
Segment profitBiological Assessment Systems ¥-10,972 thousand, Healthcare Support ¥10,883 thousand (YoY -28.2%), Cosmetics ¥-147,774 thousand, Health Supplements ¥-267,347 thousand, Functional Materials Development ¥-7,567 thousand
Outlook and shareholder returns
Revision to Earnings ForecastUnchanged
Factors Behind Changes in Business Performance
化粧品事業では、中国市場向け商品の販売が日本製品の不買運動激化の影響等により大幅に減少した。健康補助食品事業では、広告料の高騰等により広告効率が悪化し、販売量が減少した。
Disclosure regarding the going concern assumption
No applicable matters
Impairment lossNo applicable matters
Breakdown of extraordinary income (loss)Extraordinary income Not disclosed / Extraordinary loss Loss on sale of fixed assets ¥134 thousand
Orders received and order backlogBiological Assessment Systems Orders received ¥98 million (YoY +91.3%) / Order backlog ¥124 million (YoY -23.7%) / Pharmaceutical Clinical Research Support Orders received ¥18 million (YoY -57.3%) / Order backlog ¥63 million (YoY -69.6%) / Healthcare Support Orders received ¥157 million (YoY +6.6%) / Order backlog No
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2023年7月1日〜2023年9月30日 |
| Net Sales | ¥1,124,626 thousand (YoY -49.3%) |
| Operating profit | ¥-501,031 thousand |
| Ordinary income | ¥-496,402 thousand |
| Profit attributable to owners of the parent | ¥-527,096 thousand |
| Total assets | ¥7,415,538 thousand |
| Net assets | ¥6,513,457 thousand |
| Revision to Earnings Forecast | Unchanged |
| Segment revenue | Biological Assessment Systems ¥57,145 thousand (YoY -35.9%), Healthcare Support ¥157,441 thousand (YoY +6.6%), Cosmetics ¥165,871 thousand (YoY -85.1%), Health Supplements ¥676,141 thousand (YoY -7.6%), Functional Materials Development ¥67,426 thousand (YoY -51.0%) |
| Segment profit | Biological Assessment Systems ¥-10,972 thousand, Healthcare Support ¥10,883 thousand (YoY -28.2%), Cosmetics ¥-147,774 thousand, Health Supplements ¥-267,347 thousand, Functional Materials Development ¥-7,567 thousand |
| Orders received and order backlog | Biological Assessment Systems Orders received ¥98 million (YoY +91.3%) / Order backlog ¥124 million (YoY -23.7%) / Pharmaceutical Clinical Research Support Orders received ¥18 million (YoY -57.3%) / Order backlog ¥63 million (YoY -69.6%) / Healthcare Support Orders received ¥157 million (YoY +6.6%) / Order backlog No |
| Impairment loss | No applicable matters |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Loss on sale of fixed assets ¥134 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Factors Behind Changes in Business Performance | 化粧品事業では、中国市場向け商品の販売が日本製品の不買運動激化の影響等により大幅に減少した。健康補助食品事業では、広告料の高騰等により広告効率が悪化し、販売量が減少した。 |
Items this document does not state (20)
Net income per shareOperating MarginEquity ratioCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodFull-year earnings forecastAnnual Dividend ForecastPayout ratioShareholder Return PolicyRegional salesDepreciation and amortizationChange in accounting policyChanges in the scope of consolidationMaterial subsequent eventsAvailability of Supplementary Financial Results MaterialsAvailability of Financial Results BriefingIssued Shares at Period-EndTreasury Shares at Period-End
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.化粧品事業では、福島第一原発処理水の海洋放出を発端とする日本製品の不買運動激化により中国市場向け商品の販売が大幅に減少した。健康補助食品事業では、広告料の高騰等により広告効率が悪化し、販売量が減少した。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.